Michael Franken, M.D. has been appointed president of Momenta Pharmaceuticals’ Biosimilars Business and will serve as a member of the executive committee. Dr. Franken will oversee the operational management of the company’s biosimilars program, including its collaboration with Baxter International Inc., strategic planning, P&L responsibility, and other supporting activities. Dr. Franken will report to Craig Wheeler, Momenta’s president and chief executive officer.   Dr. Franken previou...